Phivida Holdings Inc. (
CNX: C.VIDA,
OTC:PHVAF,
Forum) said Monday a wholly-owned U.S. operating subsidiary has entered into an agreement with Artelo Biosciences to carry out a Pharmacokinetic (PK) study on its hem derived nonencapsulated cannabidiol (CBD) at the University of Nottingham, School of Medicine at the Royal Derby Hospital, England.
The study will test the encapsulated CBD and measure how fast and how much CBD enters the blood stream after oral consumption with each of the different formulations.
More information can be found
here.
Phivida was in the news recently when the company said it has entered into a distribution agreement with Green Reef Distributing Inc. to distribute its products across the State of California.
“We are excited to be the first state to launch Phivida’s line of branded CBD-infused functional foods, beverages and clinical products into the US marketplace,” said Nick Gagliardi, President and CEO of Green Reef Distribution Inc.
“These products will be available to retail customers through 550 dispensaries across the State of California – a market for CBD-based products that is growing exponentially as active people and families discover the benefits of CBD from hemp oil.’’
Phivida is a premier brand of cannabidiol-infused functional foods, beverages, and clinical products.
Full Disclosure: Phivida Holdings Inc.
is a paid client of Stockhouse Publishing.